反攻来了！AH创新药齐升，高弹性港股通创新药ETF（520880）冲击3%！全市场唯一药ETF溢价上涨

Core Viewpoint - The innovative drug sector is experiencing a rebound in both Hong Kong and A-share markets, driven by recent positive developments and increased investor interest in innovative drug ETFs [1][3][5]. Group 1: Market Performance - Hong Kong's innovative drug sector saw significant gains, with companies like InnoCare Pharma-B rising by 8% and Lepu Biopharma-B increasing over 5% [1]. - The A-share market's only drug ETF (562050) reached a premium of 1.67%, with leading stocks like Zai Lab Ltd. rising over 4% [3][12]. - The Hong Kong innovative drug ETF (520880) experienced a net subscription for nine consecutive days, with its fund size reaching a new high of 4.178 billion [5][13]. Group 2: Regulatory Developments - The new national medical insurance catalog added 111 new drugs launched within the last five years, including 50 first-class new drugs, marking a historical high in both quantity and proportion [7][15]. - Upcoming industry events, such as the January JPM conference and significant business development transactions, are expected to provide positive catalysts for the sector [15]. Group 3: Investment Opportunities - The Hong Kong innovative drug ETF (520880) is highlighted as a top choice for investors, offering unique advantages such as a pure focus on innovative drugs and a high concentration of leading companies, with over 72% of the top ten innovative drug leaders [15][16]. - For those looking to mitigate volatility while investing in innovative drugs, the only drug ETF in the market (562050) is recommended, which includes a significant portion of traditional Chinese medicine to provide stability [16].